Shai Shimony, MD, MPH

Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management. Am J Hematol. 2025 May; 100(5):860-891. View in: Pubmed

Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia. Blood Adv. 2025 Feb 11; 9(3):617-626. View in: Pubmed

Sharpening the Tools to Get the Edge on Leukemia. Am J Hematol. 2025 May; 100(5):750-751. View in: Pubmed

Biology and Management of Acute Myeloid Leukemia With Mutated NPM1. Am J Hematol. 2025 Apr; 100(4):652-665. View in: Pubmed

Autologous stem cell transplantation for multiple myeloma patients whose myeloma-defining event was SLiM. Br J Haematol. 2025 Feb; 206(2):607-614. View in: Pubmed

Blastic plasmacytoid dendritic cell neoplasm: Extensive disease, Langer lines, and blood burden in a retrospective study of 66 cases. J Am Acad Dermatol. 2025 Mar; 92(3):628-630. View in: Pubmed

Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen. Blood Cancer J. 2024 10 31; 14(1):191. View in: Pubmed

Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML. Blood Adv. 2024 09 24; 8(18):4845-4855. View in: Pubmed

Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes. Leukemia. 2024 Sep; 38(9):1992-2002. View in: Pubmed

Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome. Leuk Lymphoma. 2024 Nov; 65(11):1541-1551. View in: Pubmed

Chronic Lymphocytic Leukemia (CLL)-Derived Extracellular Vesicles Educate Endothelial Cells to Become IL-6-Producing, CLL-Supportive Cells. Biomedicines. 2024 Jun 21; 12(7). View in: Pubmed

Organ involvement in adults with BPDCN is associated with sun exposure history, TET2 and RAS mutations, and survival. Blood Adv. 2024 06 11; 8(11):2803-2812. View in: Pubmed

Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia. Br J Haematol. 2024 Sep; 205(3):932-941. View in: Pubmed

Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study. Am J Hematol. 2024 08; 99(8):1640-1643. View in: Pubmed

Targetable leukaemia dependency on noncanonical PI3K? signalling. Nature. 2024 Jun; 630(8015):198-205. View in: Pubmed

Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia. 2024 Jul; 38(7):1494-1500. View in: Pubmed

Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia. 2024 04; 38(4):762-768. View in: Pubmed

Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia. Blood Adv. 2024 01 09; 8(1):23-36. View in: Pubmed

Tri-ing to decipher trisomy AML. Br J Haematol. 2024 Mar; 204(3):751-752. View in: Pubmed

Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia. 2024 03; 38(3):482-490. View in: Pubmed

Targetable leukemia dependency on noncanonical PI3K? signaling. bioRxiv. 2023 Dec 15. View in: Pubmed

Untangling Complexities of Acute Myeloid Leukemia Review Series. Acta Haematol. 2024; 147(2):119-121. View in: Pubmed

SOHO State of the Art Updates and Next Questions | Approach to Older Adults With Phildadelphia-Chromosome Negative Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2024 03; 24(3):133-140. View in: Pubmed

Unraveling KMT2A-rearranged ALL. Blood. 2023 11 23; 142(21):1764-1766. View in: Pubmed

Diffuse large B cell lymphoma characteristics and outcomes during the COVID-19 pandemic in two tertiary centers - an Israeli/ Italian study. Ann Hematol. 2024 Mar; 103(3):803-811. View in: Pubmed

FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients aged =60 years. Blood Adv. 2023 09 26; 7(18):5354-5358. View in: Pubmed

Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials. Blood Adv. 2023 09 26; 7(18):5234-5245. View in: Pubmed

All systems are not GO: ongoing challenges in interpreting gemtuzumab ozogamicin clinical trial results. Lancet Haematol. 2023 09; 10(9):e706-e707. View in: Pubmed

Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML - A systematic review. Leuk Res. 2023 10; 133:107368. View in: Pubmed

Incidence and predictors of anthracycline-related left ventricular dysfunction in acute myeloid leukemia. Leuk Res. 2023 09; 132:107351. View in: Pubmed

Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma-a real-world multicenter retrospective cohort study. Ann Hematol. 2023 Aug; 102(8):2127-2136. View in: Pubmed

Epidemiology and Pathogenesis of Myelodysplastic Syndrome. Cancer J. 2023 May-Jun 01; 29(3):111-121. View in: Pubmed

Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia. Blood Adv. 2023 04 11; 7(7):1092-1102. View in: Pubmed

Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS. Blood Rev. 2023 07; 60:101056. View in: Pubmed

Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023 03; 98(3):502-526. View in: Pubmed

Investigational venetoclax combination therapy in acute myeloid leukemia - a systematic review and meta-analysis. Haematologica. 2022 12 01; 107(12):2955-2960. View in: Pubmed

Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors. Leuk Lymphoma. 2023 01; 64(1):188-196. View in: Pubmed

Correction to: Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis. Ann Hematol. 2022 Sep; 101(9):2011. View in: Pubmed

Syndromes predisposing to leukemia are a major cause of inherited cytopenias in children. Haematologica. 2022 09 01; 107(9):2081-2095. View in: Pubmed

Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax. Leuk Res. 2022 11; 122:106942. View in: Pubmed

Prevalence and Clinical Characteristics of Paraproteinemia Associated with Chronic Myeloid Leukemia. Acta Haematol. 2022; 145(6):619-626. View in: Pubmed

Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis. Ann Hematol. 2022 Sep; 101(9):2001-2010. View in: Pubmed

Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis. Ann Hematol. 2022 Aug; 101(8):1719-1726. View in: Pubmed

Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy. Blood Adv. 2022 05 10; 6(9):2835-2846. View in: Pubmed

Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes. Curr Opin Hematol. 2022 03 01; 29(2):63-73. View in: Pubmed

Autoimmune and inflammatory manifestations associated with acute myeloid leukemia with Trisomy 8-Case series and review of the literature. Eur J Haematol. 2022 Mar; 108(3):199-203. View in: Pubmed

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study. Ann Hematol. 2022 Feb; 101(2):379-387. View in: Pubmed

Maintenance therapy after allogeneic hematopoietic transplant for acute myeloid leukemia: a systematic review and meta-analysis. Acta Oncol. 2021 Oct; 60(10):1335-1341. View in: Pubmed

Late onset neutropenia after rituximab and obinutuzumab treatment - characteristics of a class-effect toxicity. Leuk Lymphoma. 2021 12; 62(12):2921-2927. View in: Pubmed

Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients - a multicenter retrospective observational study. Leuk Lymphoma. 2021 10; 62(10):2475-2481. View in: Pubmed

Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors. J Thromb Haemost. 2021 05; 19(5):1250-1258. View in: Pubmed

Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies. Hematol Oncol. 2020 Oct; 38(4):584-588. View in: Pubmed

Early detection of infectious complications during induction therapy for acute leukemia with serial C-reactive protein biomarker assessment. Leuk Lymphoma. 2020 11; 61(11):2708-2713. View in: Pubmed

Safety and efficacy of blinatumomab: a real world data. Ann Hematol. 2020 Apr; 99(4):835-838. View in: Pubmed

Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study. Hematol Oncol. 2019 Dec; 37(5):569-577. View in: Pubmed

Incidence, predictors and prognostic implications of dyspnea at admission among acute coronary syndrome patients without heart failure. Int J Cardiol. 2020 02 15; 301:29-33. View in: Pubmed

Necrotizing Hemorrhagic Gastritis following Acute Myeloid Leukemia Induction with Midostaurin: An Unexpected Complication. Acta Haematol. 2020; 143(1):65-68. View in: Pubmed

Structural and Functional Echocardiographic Changes Following Kidney Transplantation: The Role of Allograft Function. Isr Med Assoc J. 2019 Apr; 21(4):246-250. View in: Pubmed

FDG PET/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma. Hematol Oncol. 2019 Apr; 37(2):168-175. View in: Pubmed

Apixaban Levels in Octogenarian Patients with Non-valvular Atrial Fibrillation. Drugs Aging. 2019 02; 36(2):165-177. View in: Pubmed

Effects of natural and novel synthetic jasmonates in experimental metastatic melanoma. Br J Pharmacol. 2007 Mar; 150(6):738-49. View in: Pubmed